Back
Rate this talk
Your peers have not rated this talk yet.
6-minute watch | Talk 9 of 15

ASH: Expert perspective

Toxicity management after CAR T infusion

Dr Matthew Frigault
PERSPECTIVE
ASH

Dr Matthew Frigault
Massachusetts General Hospital, MA, USA

Dr Matthew Frigault of Massachusetts General Hospital, MA, USA provides his perspective on toxicity management after CAR T-cell therapy

Read more

Talks in this series

Prof. Gilles Salles presents an expert perspective (ASH Day 1 highlights)
2-minute watch | Talk 1 of 15
ASH: Expert perspective
ASH Day 1 Highlights
Prof. Gilles Salles presents an expert perspective (ASH Day 1 highlights)
2-minute watch
ASH: Expert perspective

ASH Day 1 Highlights

Dr Laurie Sehn presents an expert perspective (ASH Day 2 highlights).jpg
5-minute watch | Talk 2 of 15
ASH Day 2 Highlights
Dr Laurie Sehn
Dr Laurie Sehn presents an expert perspective (ASH Day 2 highlights).jpg
5-minute watch

ASH Day 2 Highlights

Dr Laurie Sehn

Prof. Gilles Salles presents an expert perspective (ASH Day 3 highlights)
3-minute watch | Talk 3 of 15
ASH Day 3 Highlights
Prof. Gilles Salles
Prof. Gilles Salles presents an expert perspective (ASH Day 3 highlights)
3-minute watch

ASH Day 3 Highlights

Prof. Gilles Salles

Prof. John Gribben presents an expert perspective (ZUMA 5)
5-minute watch | Talk 4 of 15
Updates on axi-cel in R/R FL
Prof. John Gribben
Prof. John Gribben presents an expert perspective (ZUMA 5)
5-minute watch

Updates on axi-cel in R/R FL

Prof. John Gribben

Dr Lori Muffly presents an expert perspective (RWE)
5-minute watch | Talk 5 of 15
Real-world evidence on the use of CAR T in R/R adult ALL
Dr Lori Muffly
Dr Lori Muffly presents an expert perspective (RWE)
5-minute watch

Real-world evidence on the use of CAR T in R/R adult ALL

Dr Lori Muffly

Dr Lori Muffly presents an expert perspective (Obe-cel)
2-minute watch | Talk 6 of 15
Updates from FELIX: obe-cel in R/R adult ALL
Dr Lori Muffly
Dr Lori Muffly presents an expert perspective (Obe-cel)
2-minute watch

Updates from FELIX: obe-cel in R/R adult ALL

Dr Lori Muffly

Prof. Eliza Hawkes presents an expert perspective (Diversity)
2-minute watch | Talk 7 of 15
Women in Lymphoma
Prof. Eliza Hawkes
Prof. Eliza Hawkes presents an expert perspective (Diversity)
2-minute watch

Women in Lymphoma

Prof. Eliza Hawkes

Dr Michael Bishop presents an expert perspective (Patient Referral and RECUR)
3-minute watch | Talk 8 of 15
If they RECUR, refer – the importance of early patient identification
Dr Michael Bishop
Dr Michael Bishop presents an expert perspective (Patient Referral and RECUR)
3-minute watch

If they RECUR, refer – the importance of early patient identification

Dr Michael Bishop

Dr Matthew Frigault presents an expert perspective (Toxicity management)
6-minute watch | Talk 9 of 15
Toxicity management after CAR T infusion
Dr Matthew Frigault
Dr Matthew Frigault presents an expert perspective (Toxicity management)
6-minute watch

Toxicity management after CAR T infusion

Dr Matthew Frigault

Dr Matthew Frigault presents an expert perspective (Sequencing CAR T and BsAbs)
2-minute watch | Talk 10 of 15
Sequencing of bispecific antibodies and CAR T cell therapy
Dr Matthew Frigault
Dr Matthew Frigault presents an expert perspective (Sequencing CAR T and BsAbs)
2-minute watch

Sequencing of bispecific antibodies and CAR T cell therapy

Dr Matthew Frigault

Dr Jason Westin presents an expert perspective (ZUMA-7, ZUMA-1 and RWE)
5-minute watch | Talk 11 of 15
Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL
Dr Jason Westin
Dr Jason Westin presents an expert perspective (ZUMA-7, ZUMA-1 and RWE)
5-minute watch

Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL

Dr Jason Westin

Dr Olalekan Oluwole presents an expert perspective (Outpatient management)
3-minute watch | Talk 12 of 15
Outpatient management in CAR T-cell therapy
Dr Olalekan Oluwole
Dr Olalekan Oluwole presents an expert perspective (Outpatient management)
3-minute watch

Outpatient management in CAR T-cell therapy

Dr Olalekan Oluwole

Dr Olalekan Oluwole presents an expert perspective (ASTCT expert panel paper)
2-minute watch | Talk 13 of 15
ASTCT Clinical Practice Guidelines for DLBCL
Dr Olalekan Oluwole
Dr Olalekan Oluwole presents an expert perspective (ASTCT expert panel paper)
2-minute watch

ASTCT Clinical Practice Guidelines for DLBCL

Dr Olalekan Oluwole

Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch | Talk 14 of 15
DESCART registry data in 2L DLBCL
Dr Gabriel Brisou
Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch

DESCART registry data in 2L DLBCL

Dr Gabriel Brisou

Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch | Talk 15 of 15
DESCART registry data in 2L DLBCL (vidéo en français)
Dr Gabriel Brisou
Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch

DESCART registry data in 2L DLBCL (vidéo en français)

Dr Gabriel Brisou

Prof. Gilles Salles presents an expert perspective (ASH Day 1 highlights)
2-minute watch | Talk 1 of 15
ASH: Expert perspective
ASH Day 1 Highlights
Prof. Gilles Salles presents an expert perspective (ASH Day 1 highlights)
2-minute watch
ASH: Expert perspective

ASH Day 1 Highlights

Dr Laurie Sehn presents an expert perspective (ASH Day 2 highlights).jpg
5-minute watch | Talk 2 of 15
ASH Day 2 Highlights
Dr Laurie Sehn
Dr Laurie Sehn presents an expert perspective (ASH Day 2 highlights).jpg
5-minute watch

ASH Day 2 Highlights

Dr Laurie Sehn

Prof. Gilles Salles presents an expert perspective (ASH Day 3 highlights)
3-minute watch | Talk 3 of 15
ASH Day 3 Highlights
Prof. Gilles Salles
Prof. Gilles Salles presents an expert perspective (ASH Day 3 highlights)
3-minute watch

ASH Day 3 Highlights

Prof. Gilles Salles

Prof. John Gribben presents an expert perspective (ZUMA 5)
5-minute watch | Talk 4 of 15
Updates on axi-cel in R/R FL
Prof. John Gribben
Prof. John Gribben presents an expert perspective (ZUMA 5)
5-minute watch

Updates on axi-cel in R/R FL

Prof. John Gribben

Dr Lori Muffly presents an expert perspective (RWE)
5-minute watch | Talk 5 of 15
Real-world evidence on the use of CAR T in R/R adult ALL
Dr Lori Muffly
Dr Lori Muffly presents an expert perspective (RWE)
5-minute watch

Real-world evidence on the use of CAR T in R/R adult ALL

Dr Lori Muffly

Dr Lori Muffly presents an expert perspective (Obe-cel)
2-minute watch | Talk 6 of 15
Updates from FELIX: obe-cel in R/R adult ALL
Dr Lori Muffly
Dr Lori Muffly presents an expert perspective (Obe-cel)
2-minute watch

Updates from FELIX: obe-cel in R/R adult ALL

Dr Lori Muffly

Prof. Eliza Hawkes presents an expert perspective (Diversity)
2-minute watch | Talk 7 of 15
Women in Lymphoma
Prof. Eliza Hawkes
Prof. Eliza Hawkes presents an expert perspective (Diversity)
2-minute watch

Women in Lymphoma

Prof. Eliza Hawkes

Dr Michael Bishop presents an expert perspective (Patient Referral and RECUR)
3-minute watch | Talk 8 of 15
If they RECUR, refer – the importance of early patient identification
Dr Michael Bishop
Dr Michael Bishop presents an expert perspective (Patient Referral and RECUR)
3-minute watch

If they RECUR, refer – the importance of early patient identification

Dr Michael Bishop

Dr Matthew Frigault presents an expert perspective (Toxicity management)
6-minute watch | Talk 9 of 15
Toxicity management after CAR T infusion
Dr Matthew Frigault
Dr Matthew Frigault presents an expert perspective (Toxicity management)
6-minute watch

Toxicity management after CAR T infusion

Dr Matthew Frigault

Dr Matthew Frigault presents an expert perspective (Sequencing CAR T and BsAbs)
2-minute watch | Talk 10 of 15
Sequencing of bispecific antibodies and CAR T cell therapy
Dr Matthew Frigault
Dr Matthew Frigault presents an expert perspective (Sequencing CAR T and BsAbs)
2-minute watch

Sequencing of bispecific antibodies and CAR T cell therapy

Dr Matthew Frigault

Dr Jason Westin presents an expert perspective (ZUMA-7, ZUMA-1 and RWE)
5-minute watch | Talk 11 of 15
Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL
Dr Jason Westin
Dr Jason Westin presents an expert perspective (ZUMA-7, ZUMA-1 and RWE)
5-minute watch

Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL

Dr Jason Westin

Dr Olalekan Oluwole presents an expert perspective (Outpatient management)
3-minute watch | Talk 12 of 15
Outpatient management in CAR T-cell therapy
Dr Olalekan Oluwole
Dr Olalekan Oluwole presents an expert perspective (Outpatient management)
3-minute watch

Outpatient management in CAR T-cell therapy

Dr Olalekan Oluwole

Dr Olalekan Oluwole presents an expert perspective (ASTCT expert panel paper)
2-minute watch | Talk 13 of 15
ASTCT Clinical Practice Guidelines for DLBCL
Dr Olalekan Oluwole
Dr Olalekan Oluwole presents an expert perspective (ASTCT expert panel paper)
2-minute watch

ASTCT Clinical Practice Guidelines for DLBCL

Dr Olalekan Oluwole

Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch | Talk 14 of 15
DESCART registry data in 2L DLBCL
Dr Gabriel Brisou
Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch

DESCART registry data in 2L DLBCL

Dr Gabriel Brisou

Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch | Talk 15 of 15
DESCART registry data in 2L DLBCL (vidéo en français)
Dr Gabriel Brisou
Dr Gabriel Brisou presents an expert perspective (DESCAR-T 2L)
3-minute watch

DESCART registry data in 2L DLBCL (vidéo en français)

Dr Gabriel Brisou

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.